Trace Neuroscience has launched its clinical development program for TRCN-1023, an experimental treatment for amyotrophic lateral sclerosis (ALS) that is designed to restore the function of UNC13A, a protein involved in nerve-muscle communication. The global clinical program includes FUNCTION ALS, a company-sponsored Phase 1/2 clinical trial authorized…
News
The lowest tested dose of Amylyx Pharmaceuticals‘ treatment candidate AMX0114 was found to be safe and well tolerated among people with amyotrophic lateral sclerosis (ALS) in an ongoing Phase 1 clinical trial. Biomarkers of nerve damage due to ALS remained relatively stable from the study’s start — a result…
The first patient has been dosed in a Phase 1/2 clinical trial evaluating Leal Therapeutics‘ LTX-002, an antisense oligonucleotide designed to target abnormalities in fat metabolism that may contribute to amyotrophic lateral sclerosis (ALS). The NeurALS trial (NCT07660614) is now recruiting an estimated 56 adults with ALS at…
Nura Bio has raised $73.8 million to support two experimental therapies designed to protect nerve cells from damage, including one that is already being tested in people with amyotrophic lateral sclerosis (ALS). Proceeds from the Series B financing round, usually the second major funding round for…
Treatment burden — the workload associated with managing a disease, including taking medications, attending medical appointments, and carrying out self-care tasks — was reported by nearly 70% of patients with amyotrophic lateral sclerosis (ALS), according to a study in Italy. Among patients reporting any burden, more than half were…
Lower blood levels of adiponectin, a signaling molecule produced by fat tissue, and the anti-inflammatory molecule interleukin (IL)-10 are associated with faster disease progression and shorter survival in people with amyotrophic lateral sclerosis (ALS), a study in China found. The findings also showed that established prognostic measures, such as…
Projenx‘s prosetin was found to be safe and well tolerated at doses that engaged its therapeutic target in people with amyotrophic lateral sclerosis (ALS), supporting its continued development as a potential disease-modifying therapy. These interim data from the fully enrolled PRO-101 Phase 1 clinical trial (NCT05279755), including…
When a parent develops amyotrophic lateral sclerosis (ALS), adult children may face heavy emotional pressures and may have difficulty balancing family, work, and personal life, highlighting the need for emotional support and guidance from both healthcare professionals and others who have gone through similar experiences. “Due to the profound…
Cases of motor neuron diseases — including amyotrophic lateral sclerosis (ALS), the most common of these — are increasing in European countries. A study suggests the reason is not solely because of an aging population, though more people are living longer and neurodegenerative diseases are more common in older…
Masitinib treatment was linked to a nearly doubled five-year survival rate among people with amyotrophic lateral sclerosis (ALS), with higher survival rates seen among patients with slower disease progression and those who started treatment before experiencing a complete loss of functionality. That’s according to new analyses from the…
Recent Posts
- New ALS treatment enters human testing in global program
- Accessible travel granted my late husband normalcy, independence
- Amylyx advancing ALS treatment in trial after early safety data is positive
- Planting seeds of hope in life with ALS
- New European trial testing safety of ALS therapy targeting fat metabolism